Biotest AG: Biotest presents gigantic artwork to visualize its sustainability initiatives

EQS-News: Biotest AG / Key word(s): Sustainability
Biotest AG: Biotest presents gigantic artwork to visualize its sustainability initiatives
01.06.2023 / 13:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

PRESS RELEASE

Biotest presents gigantic artwork to visualize its sustainability initiatives

• International Eco-Art artist creates large-scale mural to visualize company's sustainability efforts
• Special paint with sophisticated technology creates air-purifying effect
• With its GoFuture sustainability initiative, Biotest aims to grow in line with social and ecological requirements

Dreieich, 1 June 2023. Iena Cruz, a renowned Italian eco-artist, has created an impressive mural in collaboration with Biotest AG. The artwork covers an area of 750 m² on the facade of the parking garage on the company's premises in Dreieich. Iena Cruz, who lives and works in New York, is known for gigantic murals that are not only visually impressive but also made of special paint that has an air-purifying effect. The artwork in Dreieich reduces as much CO₂ as about 100 trees a year and is part of the GoFuture campaign, which aims to raise the profile of sustainability, and is a visible sign of Biotest AG's conviction and commitment to a more sustainable future. 

"With my art, I want to bring awareness to the protection of animals and their habitats by making them visible in my work," Iena Cruz explained at the inauguration of his painting. "Over the past four weeks, I have had the opportunity to both advance and visualize our shared vision of becoming more sustainable and environmentally friendly. The mural embodies the connection between humans and nature and shows the reciprocal relationship between us humans, the ecosystem and our environment."

The mural visualizes the essence and vision of Biotest, which can be described by the motto "From nature for life". By producing medications from the natural resource of blood plasma, Biotest connects plasma donors and patients. As a pharmaceutical manufacturer, the company is aware of its responsibility and places sustainability at the center of its actions. To this end, the GoFuture campaign was launched with the goal of complete climate neutrality by 2035. A crucial step towards greater sustainability is the new production facility, "Biotest Next Level," located in Dreieich. Thanks to the innovative production process, high product quality and safety are ensured. The new production facility also allows for the maximum production of plasma products from the precious donor plasma through innovative process steps, forming the basis for Biotest's medications. To ensure secure access to these vital medications for as many patients as possible in the future, Biotest relies on the indispensable willingness of many people to donate plasma and continues to expand its plasma donation centers in Europe.

However, for Biotest AG, the concept of sustainability holds a deeper meaning: "Biotest actively promotes sustainability, considering not only ecological aspects but also placing great value on social responsibility," emphasizes Dirk Neumüller, Head of Sustainability Management. "We are proud to be an employer in the Dreieich region and to provide our employees with secure jobs under good working conditions. Through our activities, we contribute to the economic stability of the region while simultaneously strengthening the secure access to life-saving medications for patients. Sustainability always remains at the center of our actions, which is why we are committed to reconciling both ecological and social aspects in order to make a positive impact."

About Biotest:

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,300 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Since May 2022, Biotest has been a part of the Grifols Group, based in Barcelona, Spain (www.grifols.com).

IR contact

Dr Monika Buttkereit

Phone: +49-6103-801-4406
Mail: ir@biotest.com

PR contact

Dirk Neumüller

Phone: +49-6103-801-269
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.com

Ordinary shares: securities’ ID No. 522720; ISIN: DE0005227201
Preference shares: securities’ ID No.  522723; ISIN: DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hannover, München, Stuttgart, Tradegate

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

01.06.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com